Clinical Trials
23
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
- Conditions
- AllergyPeanut Allergy
- First Posted Date
- 2025-06-04
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 480
- Registration Number
- NCT07003919
- Locations
- 🇺🇸
AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham Pediatric Primary Care Clinic, Birmingham, Alabama, United States
🇺🇸University of Arizona Asthma and Airway Disease Research Center, Tucson, Arizona, United States
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 600
- Registration Number
- NCT05741476
- Locations
- 🇬🇧
DBV Investigative Site, Southampton, United Kingdom
🇺🇸DBV Investigative site, Atlanta, Georgia, United States
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
- Conditions
- Peanut Allergy
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- DBV Technologies
- Registration Number
- NCT05424731
- Locations
- 🇺🇸
Early Access Care, LLC, Madison, Connecticut, United States
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
- Conditions
- Cow's Milk Allergy
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 230
- Registration Number
- NCT04492683
- Locations
- 🇺🇸
Titan Clinical Research, Phoenix, Arizona, United States
🇺🇸University of Arizona Health Science, Tucson, Arizona, United States
🇺🇸University of California, Rady Children's Hospital, San Diego, California, United States
Viaskin® Peanut (DBV712) Expanded Access Protocol
- Conditions
- Peanut Allergy
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- DBV Technologies
- Registration Number
- NCT04371627
- Prev
- 1
- 2
- 3
- 4
- Next
News
DBV Technologies Initiates COMFORT Toddlers Phase 3 Study for Viaskin Peanut Patch in Young Children
DBV Technologies has begun screening the first subject in its COMFORT Toddlers Phase 3 supplemental safety study, evaluating the Viaskin Peanut patch 250 μg in peanut-allergic children ages 1-3 years old.
Isomorphic Labs Secures $600M to Advance AI-Powered Drug Discovery Platform
Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.
Viaskin Peanut Patch Shows Promise in Toddlers with Peanut Allergy, Gains FDA Accelerated Approval Pathway
DBV Technologies' Viaskin Peanut patch demonstrates sustained benefits over 36 months in toddlers aged 1-3, improving treatment efficacy and safety.
DBV Technologies Advances Viaskin Peanut Patch with FDA and EMA Support
DBV Technologies gains FDA agreement for Accelerated Approval of Viaskin Peanut patch in toddlers aged 1-3, pending a supplemental safety study.
DBV Technologies Concludes VITESSE Trial Screening for Viaskin Peanut Patch
DBV Technologies completed screening for its VITESSE Phase 3 trial, surpassing recruitment goals for peanut-allergic children aged 4-7.
Viaskin Peanut Allergy Patch Shows Promise in Toddlers
A clinical trial reveals that a skin patch, Viaskin, significantly increases peanut tolerance in toddlers with peanut allergies.